(Il Sole 24 Ore Radiocor) - Milano, 23 apr - The Swiss pharmaceutical group Roche said that in the first quarter sales fell 5% to 14.722 billion francs due to a stronger Swiss franc against most currencies, notably the US dollar.

At constant exchange rates, the top line grew 6%.

The group confirmed its outlook for 2026.

Roche expects an increase in sales in the mid single digit range at constant exchange rates for 2026. Core earnings per share are targeted to develop in the high single digit range at constant exchange rates.

The group expects to further increase its dividend in Swiss.

francs.

(RADIOCOR) 23-04-26 12:35:14 (0393) 5 NNNN